Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
  • 中文
  • 繁体
  • EN
    • Related Links
    Press Releases
    Home  >  News  >  Press Releases
    Press Releases Media Center
    ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA
    Release Date：2026/02/28
    Font Size

    - Mocertatug rezetecan (HS-20089, a B7-H4-Targeted ADC), as monotherapy and in combination with bevacizumab, showed anti-tumor activity with a manageable safety profile in heavily pre-treated patients with platinum-sensitive ovarian cancer (PSOC) .



    SHANGHAI, February 28, 2026 — Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma,” 03692.HK) today announced the presentation of data from two clinical studies evaluating mocertatug rezetecan (HS-20089 / GSK5733584) at the 27th European Society of Gynaecological Oncology Congress (ESGO 2026), held February 26–28, 2026, in Copenhagen, Denmark.


    Mocertatug rezetecan is a B7-H4-targeted antibody–drug conjugate (ADC) under clinical development for gynaecological cancers, including endometrial and.ovarian cancers. At ESGO 2026, data were presented evaluating mocertatug rezetecan administered as monotherapy and in combination with bevacizumab in patients with platinum-sensitive ovarian cancer (PSOC). Across the two studies, mocertatug rezetecan showed anti-tumor activity with a safety profile consistent with previous studies.


    The data were generated from two open-label studies.

    · HS-20089-201, a Phase 2 study, evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of mocertatug rezetecan in Chinese patients with recurrent or metastatic ovarian and endometrial cancer.  Results from the PSOC cohort were presented as a poster.

     

    · HS-20089-103, a Phase 1 study,  evaluating combination regimens of mocertatug rezetecan in advanced solid tumors.Data from the PSOC cohort receiving mocertatug rezetecan in combination with bevacizumab were selected for presentation as a Late-Breaking Abstract (LBA) mini-oral session.


    These findings contribute to the broader understanding and potential value of topoisomerase 1 inhibitor ADCs in platinumsensitive ovarian cancer, where long-term clinical data remain limited.

     

    In addition, previously reported data presented at the 2025 ESMO Congress and the 2025 International Gynecologic Cancer Society (IGCS) Annual Meeting showed anti-tumor activity of mocertatug rezetecan in platinum-resistant ovarian cancer (PROC)[1-2]. A Phase 3 clinical study in patients with PROC is ongoing in China (NCT06855069) and a GSK-led global Phase 3 study (NCT07286266) will be initiated in early 2026.


    The details are as follows:

    1、Poster

    ◆ Presentation Title: Mocertatug rezetecan, a B7-H4 targeted antibody drug conjugate, in patients with heavily pretreated platinum-sensitive ovarian cancer (PSOC): results of an open label, phase 2 study

    ◆ Presenting Session: Poster Walks

    ◆ Abstact No: #76/P06-01

    ◆ Presentation time: February 27, 2026 17：20-18:20(CET)

    ◆ Presenter: Guangwen Yuan（National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,China）

    ◆ Results: 

    · Mocertatug rezetecan monotherapy demonstrated promising and durable antitumor activity in heavily pretreated patients with PSOC. At a median follow-up of 16.6 (range: 0.8, 19.1) months, 3 patients achieved completed response(CR), resulting in a confirmed overall response rate (cORR) of 64.5% . The median duration of Response (mDoR) was 13.8 months and the median progression-free survival (mPFS) was 14.1 months.

    · Mocertatug rezetecan monotherapy demonstrated a manageable safety profile in PSOC, consistent with prior clinical experience. The most common grade ≥3 TEAEs were hematologic laboratory abnormalities, primarily decreased neutrophil count, decreased white blood cell count, and anaemia. 


    2、LBA-mini oral

    ◆ Presentation Title: Mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with bevacizumab in patients with platinum-sensitive ovarian cancer: results from a phase 1 study

    ◆ Presenting Session: Mini Oral Session 3: Ovarian Cancer

    ◆ Abstract No: #202/MO3-8

    ◆ Presentation time: February 27, 2026, 14:55- 15:55 PM(CET)

    ◆ Presenter: Changyu Wang(Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China）

    ◆ Results: 

    · Mocertatug rezetecan in combination with bevacizumab demonstrated promising antitumor activity in patients with PSOC. At a median follow-up of 3.9 (range: 2.8, 8.3) months, 26 patients achieved a confirmed complete response (CR) or partial response (PR), resulting in a confirmed overall response rate (cORR) of 72.2%. Two additional patients had an unconfirmed PR, and the rest 8 patients achieved stable disease (SD) with tumor shrinkage.

    · The observed safety profile of mocertatug rezetecan in combination with bevacizumab in patients with PSOC was manageable and was consistent with the known safety profiles previously reported for both mocertatug rezetecan and bevacizumab. No new or overlapping toxicity was observed.


    About mocertatug rezetecan

    Mocertatug rezetecan  is a B7-H4–targeted antibody–drug conjugate (ADC) discovered and developed by Hansoh Pharma for the treatment of ovarian cancer and other solid tumors. The programme has entered Phase 3 clinical development in China for platinum-resistant ovarian cancer and is also being evaluated in studies for endometrial cancer and other solid tumors.

    In October 2023, Hansoh Pharma granted GSK an exclusive worldwide license, excluding Chinese mainland, Hong Kong, Macau and Taiwan. GSK is advancing global development through the BEHOLD programme that includes the Phase 1/2 BEHOLD-1 (NCT06431594) and BEHOLD-2 (NCT06796907) studies. GSK will initiate multiple Phase 3 trials in ovarian and endometrial cancers in 2026, including the BEHOLDOvarian01 study (NCT07286266) and BEHOLD-Endometrial01 (NCT07286331).In May 2025, mocertatug rezetecan received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA) for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.


    About Platinum Sensitivet Ovarian Cancer

    Ovarian cancer (OC) is one of the most prevalent gynecological malignancies. In 2022, approximately 324,603 new cases of ovarian cancer were diagnosed worldwide, making it the eighth most common malignancy among women. With around 206,956 deaths that year, ovarian cancer was the eighth leading cause of cancer-related mortality among female patients. 

    In China, the incidence in 2022 was 61,060, with a mortality of 32,646[3] PSOC is primarily treated with platinum-based chemotherapy, either alone or in combination with bevacizumab[4], achieving a high initial response rate. Platinum-based therapy becomes less effective with successive recurrences[5], cumulative toxicities[6], and prior exposure to PARP inhibitors[7], highlighting the need for more effective and tolerable therapies.


    References

    1. ESMO 2025 | HANSOH PHARMA PRESENTS THE PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4-TARGETED ADC), IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC)-Press Releases-Hansoh Pharmaceutical Group Co., Ltd.

    2. HANSOH PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025-Press Releases-Hansoh Pharmaceutical Group Co., Ltd.

    3. International Agency for Research on Cancer. (2024). Cancer TODAY: GLOBOCAN 2022 (version 1.1). Retrieved April 26, 2025, from Global Cancer Observatory

    4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2025.

    5. Kessous, R, et al. Int J Cancer. 2021; 148:2304-2312.

    6. Tsao, L.R, et al. Clin Rev Allergy Immunol. 2022; 62:432-448.

    7. P Harter, et al. Ann Oncol. 2025 Feb;36(2):185-196.


    About Hansoh Pharma

    Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

    Statements

    1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.

    Forward-Looking Statements

    This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).



    Back to list
    News Recommendation